Replies to post #1847 on Celldex Therapeutics Inc (CLDX)

[make it happen]

Who said that? Looks it by financials, Phase 1 long way to go... Revenue per share $0.15 per share...Negative -74.9% qtr yoy revenue growth. Gross Profit over negative -$35,000,000...

Huge negatives-Operating Margin -987.81%, all Profitability is mid double digit negatives

Cash Flow over negative -$70,000,000

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -987.81%

Management Effectiveness
Return on Assets (ttm) -20.02%
Return on Equity (ttm) -45.84%

Income Statement
Revenue (ttm) 5.38M
Revenue Per Share (ttm) 0.15
Quarterly Revenue Growth (yoy) -74.90%
Gross Profit (ttm) -35.12M
EBITDA -49.56M
Net Income Avi to Common (ttm) -63.69M
Diluted EPS (ttm) -1.81
Quarterly Earnings Growth (yoy) N/A

Cash Flow Statement
Operating Cash Flow (ttm) -46.38M
Levered Free Cash Flow (ttm) -23.89M

[harry crumb]

That was back then, if course we shorted it then, it was a turd, now its progressed with possibilities, bio's with no proven drugs are 95% failures until they nail one, celldex may b on that track! $$$$